A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The trial aims to understand if different vaccine regimens—prototype and variant vaccines alone and in combinations—can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
NIH Begins Clinical Trial Evaluating Second COVID-19 Booster Shots in Adults
August 31, 2023
George Washington's Vaccine Research Unit is participating in the Project NextGen clinical study. Read this article on the journey to preparing the vaccines and treatments for the next outbreak.
April 20, 2023
Read more information about how The George Washington Vaccine Research Unit is looking for adolescents between the ages of 12 and 17 to participate in a Mpox vaccine trial. The need for adolescents is vital for researchers to get an approved vaccine for adolescents to prevent another outbreak.
December 8, 2022
Read more about the new hope found in Phase 1 clinical trials for the HIV vaccine.